secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wellgistics Health, Inc. (WGRX)
CIK:        0002030763
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001493152-25-024471
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wellgistics Q3 net loss widens to $33.9M ($0.46/share) on stock-based comp
--------------------------------------------------------------------------

- Q3 2025 net operating loss $33.878M vs $1.867M in Q3 2024; net loss per share $0.46 vs $0.04.
- Loss driven by increased stock-based compensation related to pre-IPO acquisition of pharmaceutical distribution unit.
- President/Interim-CEO Prashant Patel reappointed Oct 6; refocusing on EinsteinRx and Brenzavvy diabetes launch.
- Acquisition of Peek Healthcare Technologies terminated as no longer strategically aligned.
- Advanced discussions with DataVault AI (DVLT) for blockchain license in Q4 2025/Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2030763/000149315225024471/0001493152-25-024471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2030763/000149315225024471/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer